{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T11:15:55Z","timestamp":1767093355490,"version":"3.37.3"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T00:00:00Z","timestamp":1564531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-ACS-13-043-01"],"award-info":[{"award-number":["IRG-ACS-13-043-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA102713-01"],"award-info":[{"award-number":["1R01CA102713-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["IRG-13-043-01"],"award-info":[{"award-number":["IRG-13-043-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"American Cancer Society (US)","award":["IRG-13-043-01"],"award-info":[{"award-number":["IRG-13-043-01"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0219521","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T17:29:24Z","timestamp":1564594164000},"page":"e0219521","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Caveat Medicus: Clinician experiences in publishing reports of serious oncology-associated adverse drug reactions"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-5705","authenticated-orcid":true,"given":"Charles L.","family":"Bennett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Schooley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7503-4094","authenticated-orcid":true,"given":"Matthew A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-6265","authenticated-orcid":true,"given":"Bartlett J.","family":"Witherspoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanth","family":"Vemula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry C.","family":"Ausdenmoore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Tony","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Hrushesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Restaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik S.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Yarnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terence","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin B.","family":"Knopf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-1673","authenticated-orcid":true,"given":"Brian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,7,31]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/jep.12184","article-title":"Pharmacovigilance in oncology: evaluation of current practice and future perspectives","volume":"20","author":"P Baldo","year":"2014","journal-title":"J Eval Clin Pract"},{"issue":"32","key":"ref2","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2014.57.2404","article-title":"Toxicity and costs of toxicity associated with new cancer drugs: international implications","volume":"32","author":"T Hermanson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref3","article-title":"Systematic Approach to Pharmacovigilance beyond the Limits: The Southern Network on Adverse Reactions (SONAR) Projects","volume":"3","author":"KZ Lu","year":"2014","journal-title":"Adv Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archinte.167.10.1041","article-title":"Evaluation of Serious Adverse Drug Reactions","volume":"167","author":"CL Bennett","year":"2007","journal-title":"Arch Intern Med"},{"issue":"21","key":"ref5","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1001\/jama.296.21.2558-c","article-title":"Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer","volume":"296","author":"CL Bennett","year":"2006","journal-title":"JAMA"},{"issue":"17","key":"ref6","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1001\/jama.293.17.2131","article-title":"The Research on Adverse Drug Events and Reports (RADAR) project","volume":"293","author":"CL Bennett","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"CL Bennett","year":"2008","journal-title":"JAMA"},{"key":"ref8","unstructured":"Medical Devices: Cancer risk led FDA to warn against certain uses of power morcellators and recommend new labeling. United States Government Accountability Office. February 2017. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.gao.gov\/assets\/690\/683277.pdf\" xlink:type=\"simple\">https:\/\/www.gao.gov\/assets\/690\/683277.pdf<\/ext-link> (accessed 11\/20\/2018)"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cam4.1098","article-title":"Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)","volume":"6","author":"RA Sobol","year":"2017","journal-title":"Cancer Med"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2017-315629","article-title":"Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man","volume":"67","author":"HL Waldum","year":"2018","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"18","author":"A Tong","year":"2007","journal-title":"Inj for Qual in Health Care"},{"article-title":"Qualitative data analysis: an expanded sourcebook","year":"1994","author":"MD Miles","key":"ref12"},{"issue":"19","key":"ref13","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMsr0912039","article-title":"Whistle-Blowers\u2019 Experiences in Fraud Litigation against Pharmaceutical Companies","volume":"362","author":"AS Kesselheim","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1525\/maq.1990.4.4.02a00020","article-title":"A Systematic Approach for Using Qualitative Methods in Primary Prevention Research","volume":"4","author":"DG Willms","year":"1990","journal-title":"Med Anthropol Q"},{"issue":"20","key":"ref15","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1001\/jama.285.20.2604","article-title":"A qualitative study of increasing beta-blocker use after myocardial infarction: Why do some hospitals succeed?","volume":"285","author":"EH Bradley","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s11606-012-2098-1","article-title":"Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye\u2019s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)","volume":"27","author":"CL Bennett","year":"2012","journal-title":"J Gen Intern Med"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1055\/s-0032-1328890","article-title":"Underreporting of Hemorrhagic and Thrombotic Complications of Pharmaceuticals to the U.S. Food and Drug Administration: Empirical Findings for Warfarin, Clopidogrel, Ticlopidine, and Thalidomide from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"T Moore","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"ref18","first-page":"1","article-title":"The U.S. Food and Drug Administration\u2019s Mini-Sentinel program: status and direction","volume":"21","author":"R Platt","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJM199405123301920","article-title":"Evaluating drugs after their approval for clinical use","volume":"330","author":"R Woosley","year":"1994","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMp1606181","article-title":"Predicting the future- Big data, machine learning, and clinical medicine","volume":"375","author":"Z Obermeyer","year":"2016","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMsb033476","article-title":"Data safety monitoring boards","volume":"350","author":"AS Slutsky","year":"2004","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0219521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:36:02Z","timestamp":1588995362000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0219521"}},"subtitle":[],"editor":[{"given":"Paula","family":"Schaiquevich","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0219521","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,7,31]]}}}